GlassScriptPhysician profile
Mark S Kasper
NPI 1780648238
$3,595.10
in general payments reported to CMS, 2019-2025
31 companies · $820 in 2025
The $820 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $205 · 2021: $325 · 2022: $445 · 2023: $652 · 2024: $862 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $685.22 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $481.25 | 2019-2025 | Breztri, Airsupra |
| Abbvie INC. | $409.39 | 2020-2025 | |
| Lilly USA, LLC | $408.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $328.97 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $162.05 | 2021-2025 | |
| Exact Sciences Corporation | $126.37 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $114.57 | 2019-2023 | Steglujan, Segluromet, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.74 | 2022-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.78 | 2022-2023 | Ofev |
| Amgen INC. | $78.93 | 2024-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $73.17 | 2019-2025 | Veozah |
| Allergan, INC. | $62.39 | 2019-2020 | |
| Almatica Pharma LLC | $61.59 | 2025 | Loreev Xr |
| Amneal Pharmaceuticals LLC | $48.69 | 2025 | Unithroid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $39.79 | 2019 | |
| Amarin Pharma, INC. | $34.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.55 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $31.68 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.71 | 2023 | |
| Axsome Therapeutics, INC. | $26.31 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $23.87 | 2025 | Jynarque |
| Endo Pharmaceuticals INC. | $22.81 | 2020 | |
| Eisai INC. | $21.48 | 2020 | |
| Horizon Therapeutics Plc | $17.82 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.67 | 2023 | Nuzyra |
| Medtronic, INC. | $15.44 | 2024 | Closurefast |
| Genentech USA, INC. | $14.59 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.59 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.